Company Overview - Kanghui Pharmaceutical was established on December 24, 2009, with a registered capital of 99.88 million RMB, and is located in Xi'an, Shaanxi Province [3] - The company specializes in the research, development, production, and sales of traditional Chinese medicine [3] - The current chairman is Wang Yanling, and the company has 906 employees [3] Shareholder and Pledge Information - A major shareholder, Yangzhou Chuangxiang Investment Partnership, holds 5,992,800 shares, accounting for 6% of the total share capital [3] - The shareholder pledged 1,997,600 shares, which is 33.33% of their holdings and 2% of the total share capital, for financing to supplement liquidity [3] - The pledge registration was completed on July 2, 2025, with a maturity date of June 22, 2026, and the creditor is Yang Yin [3] Financial Performance - The company's revenue for 2022, 2023, and 2024 is projected to be 492 million RMB, 673 million RMB, and 562 million RMB, reflecting year-on-year growth rates of 11.01%, 36.92%, and a decline of 16.54% respectively [4] - The net profit attributable to shareholders for the same years is projected to be -63.06 million RMB, -26.16 million RMB, and -89.63 million RMB, with year-on-year changes of -272.84%, 58.52%, and -242.62% respectively [4] - The company's asset-liability ratios for the same years are 43.68%, 50.29%, and 51.96% [4] Risk Assessment - The company has a total of 99 risk alerts recorded in Tianyancha, with 159 surrounding risks, 4 historical risks, and 228 warning alerts [4]